drugset
Drugs / PLUTAVIMAB
last change Jan 2023 re-read 3 minutes ago

PLUTAVIMAB

also known as COVI-AMG · COVI-DROPS · Affinity matured covi-guard · STI-2020 · STI-2099

Monoclonal antibody

Developed for
COVID-19
Investigated by
Sorrento Therapeutics, Inc.

Trials 7

today NCT04906694 · Ph 2 NCT05074394 · Ph 2 NCT04900428 · Ph 2 NCT04771351 · Ph 2 NCT04734860 · Ph 2 NCT04738175 · Ph 1/2 NCT04584697 · Ph 1/2
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/22 trials
Phase 1/2 NCT04738175 Apr → Nov 2021 COVID-19 Sorrento Therapeutics, Inc. Withdrawn No outcome recorded
Phase 1/2 NCT04584697 Dec 2020 → Apr 2021 COVID-19 Sorrento Therapeutics, Inc. Withdrawn No outcome recorded
Phase 25 trials
Phase 2 NCT04906694 Nov 2021 → Jan 2022 COVID-19 Sorrento Therapeutics, Inc. Completed No outcome recorded
Phase 2 NCT05074394 Nov 2021 → Nov 2022 COVID-19 Sorrento Therapeutics, Inc. Withdrawn No outcome recorded
Phase 2 NCT04900428 Jul 2021 → Mar 2022 COVID-19 Sorrento Therapeutics, Inc. Terminated No outcome recorded
Phase 2 NCT04771351 Apr → Aug 2021 COVID-19 Sorrento Therapeutics, Inc. Withdrawn No outcome recorded
Phase 2 NCT04734860 Apr → Sep 2021 COVID-19 Sorrento Therapeutics, Inc. Withdrawn No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as PLUTAVIMAB ChEMBL registry synonym — accepted as the source's own label CHEMBL4650460 ↗
Known as Affinity matured covi-guard ChEMBL registry synonym — accepted as the source's own label CHEMBL4650460 ↗
Known as COVI-AMG ClinicalTrials.gov intervention name — accepted as the source's own label NCT04584697 ↗
3

NCT04738175 ↗

NCT04771351 ↗

NCT04734860 ↗
Known as COVI-DROPS ClinicalTrials.gov intervention name — accepted as the source's own label NCT04900428 ↗
2

NCT05074394 ↗

NCT04906694 ↗
Known as STI-2020 ChEMBL registry synonym — accepted as the source's own label CHEMBL4650460 ↗
Known as STI-2099 “Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US)” NCT04906694 ↗
Action Inhibit “COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb).” NCT04584697 ↗
Modality Monoclonal antibody “COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb).” NCT04584697 ↗
Route Intravenous “via IV push” NCT04738175 ↗